News BeiGene abandons TIGIT antibody after lung cancer flop BeiGene has decided to stop the development of its TIGIT-targeting drug ociperlimab in yet another setback for the drug class.
News EU OK sets up first ex-China launches for BeiGene's Tevimbra BeiGene has claimed a second EU approval for PD-1 inhibitor tislelizumab in non-small cell lung cancer (NSCLC), opening the door to the first launches of the drug outside
News After FDA says no, Bayer bags EU nod for twice-yearly Eylea Bayer has been given a leg up in the competitive market for VEGF therapies used to treat eye diseases with a new EU approval for Eylea 8mg.
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face
